Literature DB >> 25365068

Pre-transplantation risk factors to develop sclerotic chronic GvHD after allogeneic HSCT: a multicenter retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

M Y Detrait1, S Morisset2, R Peffault de Latour3, I Yakoub-Agha4, R Crocchiolo5, R Tabrizi6, J-O Bay7, P Chevalier8, F Barraco1, N Raus9, S Vigouroux6, L Magro4, M Mohty8, N Milpied6, D Blaise5, G Socié3, M Michallet1.   

Abstract

Sclerotic chronic GvHD (cGvHD) is one of the most severe complications after allo-hematopoietic stem cell transplantation (HSCT). Risk factors associated with this complication remain not very well defined. With the aim to define a pre-transplantation risk profile, we have conducted a French retrospective analysis in 705 consecutive patients between 2005 and 2010. Analyses to determine pre-transplantation risk factors included as variables: patient and donor age, kind of donor, HLA matching, ABO matching, sex-matching, diagnosis, stem cell source, gender, GvHD prophylaxis and antithymocyte globulin (ATG) in the conditioning regimen. The cumulative incidence of sclerotic cGvHD was 18% (95% CI, 16.6-19.6) 3 years after onset of cGvHD. In univariate analysis, we found a significantly lower number of sclerotic cGvHD form in patients transplanted from cord blood cells (P=0.0021), in patients with a one mismatched donor (P=0.041) and in patients who had received ATG in the conditioning regimen (P=0.002). In multivariate analysis, factors associated with an increased risk of sclerotic cGvHD were young patient age, multiple myeloma and PBSC as the stem cell source. ATG in conditioning regimen and cord blood unit as the stem cell source were associated with a lower risk.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25365068     DOI: 10.1038/bmt.2014.244

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  31 in total

1.  Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation.

Authors:  Andrea Bacigalupo; Teresa Lamparelli; Giovanni Barisione; Paolo Bruzzi; Stefano Guidi; Paolo Emilio Alessandrino; Paolo di Bartolomeo; Rosi Oneto; Barbara Bruno; Nicoletta Sacchi; Maria Teresa van Lint; Alberto Bosi
Journal:  Biol Blood Marrow Transplant       Date:  2006-05       Impact factor: 5.742

2.  Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro.

Authors:  Xingmin Feng; Sachiko Kajigaya; Elena E Solomou; Keyvan Keyvanfar; Xiuli Xu; Nalini Raghavachari; Peter J Munson; Thomas M Herndon; Jichun Chen; Neal S Young
Journal:  Blood       Date:  2008-02-04       Impact factor: 22.113

3.  Sjögren-type syndrome after allogeneic bone-marrow transplantation.

Authors:  A A Gratwohl; A A Gratwhol; H M Moutsopoulos; T M Chused; M Akizuki; R O Wolf; J B Sweet; A B Deisseroth
Journal:  Ann Intern Med       Date:  1977-12       Impact factor: 25.391

4.  Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease.

Authors:  Yoshihiro Inamoto; Barry E Storer; Effie W Petersdorf; J Lee Nelson; Stephanie J Lee; Paul A Carpenter; Brenda M Sandmaier; John A Hansen; Paul J Martin; Mary E D Flowers
Journal:  Blood       Date:  2013-04-01       Impact factor: 22.113

5.  Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis.

Authors:  C Cutler; S Giri; S Jeyapalan; D Paniagua; A Viswanathan; J H Antin
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

6.  Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody.

Authors:  Voravit Ratanatharathorn; Lois Ayash; Christopher Reynolds; Samuel Silver; Pavan Reddy; Michael Becker; James L M Ferrara; Joseph P Uberti
Journal:  Biol Blood Marrow Transplant       Date:  2003-08       Impact factor: 5.742

7.  Peripheral-blood stem cells versus bone marrow from unrelated donors.

Authors:  Claudio Anasetti; Brent R Logan; Stephanie J Lee; Edmund K Waller; Daniel J Weisdorf; John R Wingard; Corey S Cutler; Peter Westervelt; Ann Woolfrey; Stephen Couban; Gerhard Ehninger; Laura Johnston; Richard T Maziarz; Michael A Pulsipher; David L Porter; Shin Mineishi; John M McCarty; Shakila P Khan; Paolo Anderlini; William I Bensinger; Susan F Leitman; Scott D Rowley; Christopher Bredeson; Shelly L Carter; Mary M Horowitz; Dennis L Confer
Journal:  N Engl J Med       Date:  2012-10-18       Impact factor: 91.245

8.  Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD.

Authors:  L Magro; B Catteau; V Coiteux; B Bruno; J-P Jouet; I Yakoub-Agha
Journal:  Bone Marrow Transplant       Date:  2008-09-01       Impact factor: 5.483

9.  Sclerodermatous chronic graft-versus-host disease. Analysis of seven cases.

Authors:  O Chosidow; M Bagot; J P Vernant; J C Roujeau; C Cordonnier; M Kuentz; J Wechsler; C André; R Touraine; J Revuz
Journal:  J Am Acad Dermatol       Date:  1992-01       Impact factor: 11.527

10.  An analysis of factors predisposing to chronic graft-versus-host disease.

Authors:  O Ringdén; T Paulin; B Lönnqvist; B Nilsson
Journal:  Exp Hematol       Date:  1985-11       Impact factor: 3.084

View more
  4 in total

1.  Motor ability, function, and health-related quality of life as correlates of symptom burden in patients with sclerotic chronic graft-versus-host disease receiving imatinib mesylate.

Authors:  Emily A Rosenthal; Pei-Shu Ho; Galen O Joe; Sandra A Mitchell; Susan Booher; Steven Z Pavletic; Kristin Baird; Edward W Cowen; Leora E Comis
Journal:  Support Care Cancer       Date:  2019-12-06       Impact factor: 3.603

2.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report.

Authors:  Joseph Pidala; Carrie Kitko; Stephanie J Lee; Paul Carpenter; Geoffrey D E Cuvelier; Shernan Holtan; Mary E Flowers; Corey Cutler; Madan Jagasia; Ted Gooley; Joycelynne Palmer; Tim Randolph; John E Levine; Francis Ayuk; Fiona Dignan; Helene Schoemans; Eric Tkaczyk; Nosha Farhadfar; Anita Lawitschka; Kirk R Schultz; Paul J Martin; Stefanie Sarantopoulos; Yoshihiro Inamoto; Gerard Socie; Daniel Wolff; Bruce Blazar; Hildegard Greinix; Sophie Paczesny; Steven Pavletic; Geoffrey Hill
Journal:  Transplant Cell Ther       Date:  2021-04-06

3.  Disability related to chronic graft -versus-host disease after alternative donor hematopoietic cell transplantation.

Authors:  Giancarlo Fatobene; Barry E Storer; Rachel B Salit; Stephanie J Lee; Paul J Martin; Guang-Shing Cheng; Paul A Carpenter; Gansuvd Balgansuren; Effie W Petersdorf; Colleen Delaney; Brenda M Sandmaier; Filippo Milano; Mary E Flowers
Journal:  Haematologica       Date:  2018-11-15       Impact factor: 9.941

4.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report.

Authors:  Daniel Wolff; Vedran Radojcic; Robert Lafyatis; Resat Cinar; Rachel K Rosenstein; Edward W Cowen; Guang-Shing Cheng; Ajay Sheshadri; Anne Bergeron; Kirsten M Williams; Jamie L Todd; Takanori Teshima; Geoffrey D E Cuvelier; Ernst Holler; Shannon R McCurdy; Robert R Jenq; Alan M Hanash; David Jacobsohn; Bianca D Santomasso; Sandeep Jain; Yoko Ogawa; Philipp Steven; Zhonghui Katie Luo; Tina Dietrich-Ntoukas; Daniel Saban; Ervina Bilic; Olaf Penack; Linda M Griffith; Meredith Cowden; Paul J Martin; Hildegard T Greinix; Stefanie Sarantopoulos; Gerard Socie; Bruce R Blazar; Joseph Pidala; Carrie L Kitko; Daniel R Couriel; Corey Cutler; Kirk R Schultz; Steven Z Pavletic; Stephanie J Lee; Sophie Paczesny
Journal:  Transplant Cell Ther       Date:  2021-06-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.